Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S475000, C549S090000, C549S512000
Reexamination Certificate
active
07144917
ABSTRACT:
The invention provides compounds that inhibit MMPs; methods for treating or preventing cancer, angiogenesis, arthritis, connective tissue disease, cardiovascular disease, inflammation or autoimmune disease in a mammal; a method for inhibiting a matrix metalloproteinase in vivo or in vitro; and a method for imaging a tumor in vivo or in vitro.
REFERENCES:
patent: 2949474 (1960-08-01), Murdoch et al.
patent: 2965651 (1960-12-01), Kosmin et al.
patent: 3222326 (1965-12-01), Brodoway
patent: 4797218 (1989-01-01), Steinberg et al.
patent: 5288722 (1994-02-01), Kishimoto et al.
patent: 5981763 (1999-11-01), Garapon et al.
patent: WO-95/35275 (1995-12-01), None
patent: WO-97/18231 (1997-05-01), None
patent: WO-98/33788 (1998-08-01), None
Beckett, R. P., et al., “Recent Advances in Matrix Metalloproteinase Inhibitor Research”,Drug Discovery Today, 1(1), (Jan. 1996), 16-26.
Brew, K., et al., “Tissue Inhibitors of Metalloproteinases: Evolution, Structure and Function”,Biochimica et Biophysica Acta, 1477(1-2), (Mar. 7, 2000),267-283.
Brown, Stephen, et al., “Potent and Selective Mechanism-Based Inhibition of Gelatinases”,Journal of the American Chemical Society, 122(28), (Jul. 19, 2000),6799-6800.
Bulychev, A., et al., “N-Sulfonyloxy-beta-lactam Inhibitors for beta-Lactamases”,Tetrahedron, 56(31), (Jul. 28, 2000),5719-5728.
Dalberg, Kristina, et al., “Gelatinase A, Membrane Type 1 Matrix Metalloproteinase, and Extracellular Matrix Metalloproteinase Inducer mRNA Expression: Correlation with Invasive Growth of Breast Cancer”,World Journal of Surgery, 24(3), (Mar. 2000),334-340.
Dumas, V., et al., “Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas”,Anticancer Research, 19(4B), (Jul.-Aug. 1999),2929-2938.
Forget, Marie-Annick, et al., “Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis”,Canadian Journal of Physiology and Pharmacology, 77, (1999),465-480.
Freskos, J., et al., “Discovery of a Novel Series of Selective MMP Inhibitors: Identification of the γ-Sulfone-Thiols”,Bioorganic&Medicinal Chemistry Letters, 9(7), (Apr. 5, 1999),943-948.
Fridman, R., et al., “Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions”,Journal of Biological Chemistry, 267(22), (Aug. 5, 1992),15398-15405.
Fridman, R., et al., “Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme”,Biochemical Journal, 289(Pt 2), (Jan. 15, 1993),411-416.
Greenwald, R A., et al., “Thirty-six Years in the Clinic without an MMP Inhibitor: What Hath Collagenase Wrought?”,Annals of the New York Academy of Sciences, 878,(Jun. 1999),412-419.
Knight, C G., “Fluorimetric assays of proteolytic enzymes”,Methods in Enzymology, 248, (1995),18-34.
Massova, Irina, et al., “Matrix Metalloproteinases: Structures, Evolution, and Diversification”,FASEB Journal, 12(12), (Sep. 1998),1075-1095.
Massova, Irina, et al., “Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities”,Journal of Molecular Modeling, 3(1). (Jan. 1997),17-30.
Michaelides, M. R., et al., “Recent advances in matrix metalloproteinase inhibitors research”,Current Pharmaceutical Design, 5(10), (Oct. 1999),787-819.
Morgunova, Ekaterinia, et al., “Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism Revealed”,Science, 284(5420), (Jun. 4, 1999),1667-1670.
Nelson, Amy R., et al., “Matrix Metalloproteinases: Biologic Activity and Clinical Implications”,Journal of Clinical Oncology, 18(5), (Mar. 1, 2000),1135-1149.
Olson, Matthew W., et al., “Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9, Differential rates for activation by stromelysin 1”,Journal of Biological Chemistry, 275(4), (Jan. 28, 2000),2661-2668.
Pyke, C., et al., “Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization”,Cancer Research, 52(5), (Mar. 1, 1992),1336-1341.
Salo, Tuula, et al., “Purification and Characterization of a Murine Basement Membrane Collagen-degrading Enzyme Secreted by Metastatic Tumor Cells”,Journal of Biological Chemistry, 258(5), (Mar. 10, 1983),3058-3063.
Tamura, Y., “Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives”,Journal of Medicinal Chemistry, 41(4), (Feb. 12, 1998),640-649.
Westermarck, Jukka, et al., “Regulation of Matrix metalloproteinase Expression in Tumor Invasion”,FASEB Journal, 13(8), (May 1999),781-792.
Fridman Rafael
Mobashery Shahriar
Lambkin Deborah C.
Schwegman Lundberg Woessner & Kluth P.A.
Wayne State University
LandOfFree
Inhibitors of matrix metalloproteinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of matrix metalloproteinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of matrix metalloproteinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718447